Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.028x

Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥103.70 Million ≈ $15.17 Million USD) by net assets (CN¥3.76 Billion ≈ $550.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 600645 net asset quality score to measure how much of total assets are equity-financed.

Vcanbio Cell & Gene Engineering Corp Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)

This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 600645 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vcanbio Cell & Gene Engineering Corp Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Batisoke Soke Cimento Sanayi TAS IS:BSOKE	0.033x
Huizhou Speed Wireless Technology Co Ltd SHE:300322	-0.085x
ROMANDE ENERGIE SA SW:REHN	0.072x
Morgan Stanley Direct Lending Fund NYSE:MSDL	0.051x
Forbo Holding AG SW:FORN	-0.024x
ACV Auctions Inc. NASDAQ:ACVA	0.024x
Kailuan Energy Chemical Co Ltd SHG:600997	0.020x
Energizer Holdings Inc NYSE:ENR	-0.010x

Annual Cash Flow Conversion Efficiency for Vcanbio Cell & Gene Engineering Corp Ltd (1998–2025)

The table below shows the annual cash flow conversion efficiency of Vcanbio Cell & Gene Engineering Corp Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Vcanbio Cell & Gene Engineering Corp Ltd stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥3.75 Billion ≈ $549.45 Million	CN¥313.63 Million ≈ $45.89 Million	0.084x	+7.17%
2024-12-31	CN¥3.66 Billion ≈ $535.44 Million	CN¥285.19 Million ≈ $41.73 Million	0.078x	-0.99%
2023-12-31	CN¥3.80 Billion ≈ $555.86 Million	CN¥299.02 Million ≈ $43.76 Million	0.079x	+9.82%
2022-12-31	CN¥3.65 Billion ≈ $534.64 Million	CN¥261.89 Million ≈ $38.32 Million	0.072x	-21.10%
2021-12-31	CN¥3.53 Billion ≈ $516.95 Million	CN¥320.96 Million ≈ $46.97 Million	0.091x	+30.22%
2020-12-31	CN¥3.50 Billion ≈ $512.51 Million	CN¥244.35 Million ≈ $35.76 Million	0.070x	-0.02%
2019-12-31	CN¥3.46 Billion ≈ $506.41 Million	CN¥241.49 Million ≈ $35.34 Million	0.070x	+60.09%
2018-12-31	CN¥2.98 Billion ≈ $436.71 Million	CN¥130.08 Million ≈ $19.04 Million	0.044x	+1.38%
2017-12-31	CN¥1.63 Billion ≈ $239.17 Million	CN¥70.27 Million ≈ $10.28 Million	0.043x	-47.58%
2016-12-31	CN¥1.75 Billion ≈ $256.34 Million	CN¥143.67 Million ≈ $21.02 Million	0.082x	+1587.16%
2015-12-31	CN¥1.68 Billion ≈ $246.10 Million	CN¥8.17 Million ≈ $1.20 Million	0.005x	-97.46%
2014-12-31	CN¥1.16 Billion ≈ $169.20 Million	CN¥221.45 Million ≈ $32.41 Million	0.192x	+14.17%
2013-12-31	CN¥660.07 Million ≈ $96.59 Million	CN¥110.72 Million ≈ $16.20 Million	0.168x	-32.93%
2012-12-31	CN¥281.54 Million ≈ $41.20 Million	CN¥70.41 Million ≈ $10.30 Million	0.250x	-39.12%
2011-12-31	CN¥268.85 Million ≈ $39.34 Million	CN¥110.44 Million ≈ $16.16 Million	0.411x	-42.99%
2010-12-31	CN¥244.13 Million ≈ $35.72 Million	CN¥175.93 Million ≈ $25.74 Million	0.721x	+38.01%
2009-12-31	CN¥239.23 Million ≈ $35.01 Million	CN¥124.92 Million ≈ $18.28 Million	0.522x	+10.06%
2008-12-31	CN¥256.31 Million ≈ $37.51 Million	CN¥121.60 Million ≈ $17.79 Million	0.474x	-21.23%
2007-12-31	CN¥185.42 Million ≈ $27.13 Million	CN¥111.68 Million ≈ $16.34 Million	0.602x	+45.63%
2006-12-31	CN¥184.04 Million ≈ $26.93 Million	CN¥76.12 Million ≈ $11.14 Million	0.414x	-19.44%
2005-12-31	CN¥164.95 Million ≈ $24.14 Million	CN¥84.69 Million ≈ $12.39 Million	0.513x	+175.49%
2004-12-31	CN¥309.95 Million ≈ $45.36 Million	CN¥57.76 Million ≈ $8.45 Million	0.186x	+62.98%
2003-12-31	CN¥365.02 Million ≈ $53.41 Million	CN¥41.74 Million ≈ $6.11 Million	0.114x	+377.40%
2002-12-31	CN¥357.83 Million ≈ $52.36 Million	CN¥-14.75 Million ≈ $-2.16 Million	-0.041x	+75.21%
2001-12-31	CN¥414.06 Million ≈ $60.59 Million	CN¥-68.84 Million ≈ $-10.07 Million	-0.166x	-327.53%
2000-12-31	CN¥433.95 Million ≈ $63.50 Million	CN¥31.71 Million ≈ $4.64 Million	0.073x	+632.86%
1999-12-31	CN¥414.12 Million ≈ $60.60 Million	CN¥4.13 Million ≈ $604.18K	0.010x	+112.92%
1998-12-31	CN¥416.47 Million ≈ $60.94 Million	CN¥-32.14 Million ≈ $-4.70 Million	-0.077x	--

About Vcanbio Cell & Gene Engineering Corp Ltd

SHG:600645 China Biotechnology

Market Cap

$1.29 Billion

CN¥8.83 Billion CNY

Market Cap Rank

#7799 Global

#1759 in China

Share Price

CN¥18.87

Change (1 day)

-0.42%

52-Week Range

CN¥16.74 - CN¥32.94

All Time High

CN¥68.93